The Australasian Society of Clinical Immunology and Allergy (ASCIA) was established in 1990 as the peak professional body for allergy and clinical immunology in Australia and New Zealand. ASCIA is a member society of the World Allergy Organisation (WAO) and a specialty society affiliated with the Royal Australasian College of Physicians (RACP).

ASCIA currently represents 680 members, including clinical immunology/allergy specialists and other health professionals who work in the areas of allergy and clinical immunology.

1. Don't use antihistamines to treat anaphylaxis – prompt administration of adrenaline is the only treatment for anaphylaxis.

2. Alternative/unorthodox methods should not be used for allergy testing or treatment.

3. Allergen immunotherapy should not be used for routine treatment of food allergy – research in this area is ongoing.

4. Food specific IgE testing should not be performed without a clinical history suggestive of IgE-mediated food allergy.

5. Don't delay introduction of solid foods to infants - ASCIA Guidelines for Infant Feeding and allergy prevention recommend introduction of solid foods to infants, around six months of age.
Don’t use antihistamines to treat anaphylaxis – prompt administration of adrenaline (epinephrine) is the only treatment for anaphylaxis.

For emergency treatment of a severe allergic reaction (anaphylaxis), it is important to promptly administer adrenaline (epinephrine) by intramuscular injection using an adrenaline autoinjector if available, or by using adrenaline ampoules and syringe (the latter is only suitable in a medical setting).

There is a high risk of potential harm (disability or death) from anaphylaxis if it is not treated promptly with adrenaline.

There are also cost implications from delayed or inappropriate treatment of anaphylaxis, such as additional ambulance, emergency department and hospital costs, as well as additional anxiety for patients and their families or carers.

Antihistamines are recommended for treatment of mild and moderate allergic reactions, including allergic rhinitis (hay fever), but have no role in treating or preventing respiratory and cardiovascular symptoms of anaphylaxis.

In particular, oral sedating antihistamines should never be used in patients with anaphylaxis as side effects (drowsiness or lethargy) may mimic some signs of anaphylaxis. Injectable promethazine should not be used in anaphylaxis as it can worsen hypotension and cause muscle necrosis.

For further information go to www.allergy.org.au/anaphylaxis

Alternative/unorthodox methods should not be used for allergy testing or treatment.

Whilst there is currently no cure for allergy, reliable tests and a range of treatments for allergy are available, which are backed up by scientific studies that demonstrate proven safety and efficacy.

In contrast, numerous studies have demonstrated the uselessness of several alternative/unorthodox methods that claim to test or treat allergy. These methods continue to be promoted in the community and some even make false claims that they can cure allergy. There is also currently no stringent regulation of alternative/unorthodox diagnostic techniques and devices, so they can be “listed” in Australia without having to prove that they work.

There is a risk of potential harm if individuals with allergies are incorrectly diagnosed and inappropriately treated using alternative/unorthodox methods, particularly if they have severe allergies. The costs of alternative/unorthodox methods are significant, and are usually paid for by individuals, with rebates from some private health funds. There are cost implications for healthcare services as well as individuals, as these funds are being directed into non-productive areas, and are therefore not available for more useful medical tests and treatments.

Examples of alternative/unorthodox methods that have been demonstrated to lack evidence for testing or treating allergy include food specific IgG and IgG4 tests, homeopathy, cytotoxic testing and kinesiology.

For further information go to www.allergy.org.au/patients/allergy-testing
**Allergen immunotherapy should not be used for routine treatment of food allergy – research in this area is ongoing.**

Research into allergen immunotherapy for food allergy is ongoing and until further work determining safety and efficacy is determined, it should not be performed outside of well-defined medical research studies, as there is a high risk of potential harm in individuals with severe food allergy.

Allergen immunotherapy is currently only recommended for treatment of allergic rhinitis (hay fever) and sometimes allergic asthma, due to environmental allergens (such as pollen or dust mites) and for the treatment of stinging insect allergy. Allergen immunotherapy should be considered in appropriate patients when symptoms are severe, the cause is difficult to avoid (such as grass pollen or stinging insects) and medications don’t help or cause adverse side effects.

For further information go to www.allergy.org.au/patients/allergy-treatment

**Food specific IgE testing should not be performed without a clinical history suggestive of IgE-mediated food allergy.**

Reliable and proven diagnostic tests for food allergy include skin prick testing, blood tests for food specific IgE antibodies and medically supervised food allergen challenges. Allergy test results should never be used on their own and must be considered together with the patient’s clinical history. In the absence of a history of clinical symptoms, low levels of allergen-specific IgE are usually of little diagnostic significance.

Allergy testing of individuals where there is no evidence that food allergy plays a role in their clinical symptoms increases the likelihood of irrelevant false positive results. This may lead to potential harm due to inappropriate and unnecessary dietary restrictions, with nutritional implications for the individual (particularly in children) and unnecessary fear and anxiety (particularly for the family or carers).

For further information go to www.allergy.org.au/patients/food-allergy
Don’t delay introduction of solid foods to infants – ASCIA Guidelines for Infant Feeding and allergy prevention recommend introduction of solid foods to infants, around six months of age.

This recommendation is consistent with ASCIA Guidelines for infant feeding and allergy prevention (2016), which recommend introduction of solid foods to infants, at around six months of age, but not before four months (including foods considered to be highly allergenic such as peanut) preferably whilst breast feeding.

It is important to seek medical advice if an allergic reaction occurs and also regarding the safe introduction of foods if an infant has a sibling or parent with food allergy.

This recommendation is also consistent with findings from recent studies, including the LEAP (Learning Early About Peanut Allergy) trials published in the New England Journal of Medicine (NEJM) in 2015 and 2016. The LEAP trials concluded that the early introduction of peanuts significantly decreased (by 80%) the frequency of the development of peanut allergy among children at high risk for this allergy and modulated immune responses to peanuts.

For further information go to www.allergy.org.au/patients/allergy-prevention

WHAT IS EVOLVE?

As part of a global movement, Evolve is a flagship initiative led by physicians, specialties and the Royal Australasian College of Physicians (RACP) to drive high-value, high-quality care in Australia and New Zealand.

Evolve aims to reduce low-value care by supporting physicians to:
• be leaders in changing clinical behaviour for better patient care
• make better decisions, and
• make better use of resources.

Evolve works with specialties to identify their ‘Top-Five’ clinical practices that, in particular circumstances, may be overused, provide little or no benefit, or cause unnecessary harm. Evolve ‘Top-Five’ recommendations on low-value practices are developed through a rigorous, peer-reviewed process; led by clinical experts, informed by evidence and guided by consultation.

Evolve enables physicians to:
• safely and responsibly phase out low-value tests, treatments and procedures, where appropriate
• enhance the safety and quality of healthcare
• provide high-value care to patients based on evidence and expertise, and
• influence the best use of health resources, reducing wasted expenditure and the carbon footprint of the healthcare system.

Evolve is a founding member of Choosing Wisely Australia® and Choosing Wisely New Zealand, with all Evolve ‘Top-Five’ recommendations part of the Choosing Wisely campaign.

For the list of references supporting these recommendations and further information on the development process, see evolve.edu.au/recommendations/ASCIA.